11 recruiting. 11 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Recruiting 11 |
| Phase 2 | 2 | Recruiting 2 |
Follow Hepatitis: new trials by email Literature Review of Hepatitis trials Research Report on Hepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Inebilizumab in Participants With Autoimmune Hepatitis Inebilizumab, Placebo, Standard of Care - Autoimmune Hepatitis, AIH | Phase 3 | Recruiting | Amgen | 180 | 2026-12-18 | 2026-11-03 |
| Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL), Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL), Hepatitis A vaccine (inactivated, adsorbed) - Hepatitis A Vaccine | Phase 3 | Recruiting | Sinovac Biotech Co., Ltd | 680 | 2026-08-20 | 2026-08-28 |
| PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis N-Acetylcysteine (NAC) Treatment, Prednisolone, Placebo of N-acetylcysteine - Alcoholic Hepatitis | Phase 3 | Recruiting | University Hospital, Lille | 477 | 2026-05-22 | 2026-06-01 |
| A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study) Libevitug 20 mg/kg, Libevitug 10 mg/kg, Delayed treatment with libevitug - Chronic Hepatitis D Infection | Phase 3 | Recruiting | Huahui Health | 160 | 2026-04-22 | 2026-08-24 |
| Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Brelovitug (BJT-778), Bulevirtide - Chronic Hepatitis D | Phase 2 / Phase 3 | Recruiting | Mirum Pharmaceuticals, Inc. | 120 | 2026-02-26 | 2026-10-27 |
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) Larsucosterol, Placebo - Hepatitis | Phase 3 | Recruiting | Bausch Health Americas, Inc. | 350 | 2026-01-29 | 2026-10-15 |
| A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B AZVUDINE, TAF, IFNα-2a - Chronic Hepatitis B, Azvudine | Phase 3 | Recruiting | Zhigang Ren | 120 | 2025-09-01 | 2025-12-29 |
| A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg - Chronic Hepatitis D Infection | Phase 3 | Recruiting | Mirum Pharmaceuticals, Inc. | 172 | 2025-08-27 | 2026-10-08 |
| To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment GST-HG141, GST-HG141 Placebo - Chronic Hepatitis b | Phase 3 | Recruiting | Fujian Akeylink Biotechnology Co., Ltd. | 526 | 2025-07-24 | 2026-01-23 |
| A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. Undiluted I.V.-Hepabig inj(GC5103), Diluted I.V.-Hepabig inj(GC5103) - Hepatitis B | Phase 3 | Recruiting | GC Biopharma Corp | 105 | 2023-04-13 | 2025-06-25 |
| Faecal Microbiota Transplantation for Liver Cirrhosis Faecal microbiota transplantation, Placebo - Liver Cirrhosis | Phase 2 / Phase 3 | Recruiting | University of Aarhus | 220 | 2021-07-01 | 2025-01-24 |
Hepatitis, Alcoholic (3) · Hepatitis B, Chronic (2) · Hepatitis D (2) · Ascites (1) · Gastrointestinal Hemorrhage (1) · Hepatic Encephalopathy (1) · Hepatic Insufficiency (1) · Hepatitis B (1) · Hepatitis D, Chronic (1) · Hepatitis, Autoimmune (1) · Hepatorenal Syndrome (1) · Liver Cirrhosis (1) · Liver Diseases (1)
Digestive System Diseases (11) · Liver Diseases (10) · Hepatitis, Viral, Human (6) · Infections (6) · Virus Diseases (6) · Hepatitis, Chronic (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Alcohol-Induced Disorders (3) · Alcohol-Related Disorders (3) · Blood-Borne Infections (3) · Chemically-Induced Disorders (3) · Chronic Disease (3) · Communicable Diseases (3)
bulevirtide (2) · Acetylcysteine (1) · Fecal Microbiota Transplantation (1) · Hepatitis A Vaccines (1) · Prednisolone (1) · Standard of Care (1) · Therapeutics (1) · Treatment Delay (1) · azvudine (1) · inebilizumab (1)
Mirum Pharmaceuticals, Inc. (2) · Amgen (1) · Bausch Health Americas, Inc. (1) · Fujian Akeylink Biotechnology Co., Ltd. (1) · GC Biopharma Corp (1) · Huahui Health (1) · Sinovac Biotech Co., Ltd (1) · University Hospital, Lille (1) · University of Aarhus (1) · Zhigang Ren (1)
China (4) · France (4) · Germany (3) · Italy (3) · United States (3) · Austria (2) · Czechia (2) · Pakistan (2) · Romania (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Canada (1) · Denmark (1) · Hungary (1)
2025 (2)